Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.1M Buy
5,104
+22
+0.4% +$7.53K 0.55% 33
2026
Q1
$1.78M Buy
5,082
+20
+0.4% +$7.13K 0.52% 36
2025
Q4
$1.86M Sell
5,062
-7
-0.1% -$2.22K 0.55% 33
2025
Q3
$1.47M Buy
5,069
+70
+1% +$20.3K 0.49% 37
2025
Q2
$1.48M Sell
4,999
-191
-4% -$54.1K 0.52% 36
2025
Q1
$1.45M Buy
+5,190
New +$1.53M 0.64% 31
2024
Q3
$1.63M Buy
5,067
+23
+0.5% +$7.52K 0.64% 29
2024
Q2
$1.59M Buy
5,044
+24
+0.5% +$7.05K 0.68% 27
2024
Q1
$1.56M Buy
+5,020
New +$1.47M 0.69% 26
2023
Q3
$1.45M Buy
5,291
+30
+0.6% +$7.49K 0.76% 25
2023
Q2
$1.37M Buy
5,261
+33
+0.6% +$7.66K 0.71% 24
2023
Q1
$1.16M Buy
+5,228
New +$1.28M 0.62% 28

Other funds holding AMGN

Sweeney & Michel's AMGN Position: Q2 2026 in Review

Sweeney & Michel increased its Amgen (AMGN) stake by 0.43% in Q2 2026, buying an estimated $7.53K and bringing the position to 5,104 shares worth $2.1M. The position accounts for 0.55% of the portfolio, ranked #33.

Sweeney & Michel first reported a position in AMGN in Q1 2023 and has held it in 12 quarters since. 3,164 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Sweeney & Michel held 5,104 shares of Amgen worth $2.1M as of Q2 2026.
  • Sweeney & Michel bought 22 Amgen shares in Q2 2026, an estimated $7.53K.
  • Amgen made up 0.55% of Sweeney & Michel's portfolio in Q2 2026, its #33 holding.
  • Sweeney & Michel first reported a position in Amgen in Q1 2023 and has held it in 12 quarters since.
  • 3,164 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Sweeney & Michel's 13F filing for Q2 2026, filed 11 Aug 2026.